Bicycle Therapeutics (NASDAQ:BCYC) Announces Quarterly Earnings Results

Bicycle Therapeutics (NASDAQ:BCYC) announced its earnings results on Thursday. The company reported ($0.15) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.25, FiscalAI reports. Bicycle Therapeutics had a negative return on equity of 25.40% and a negative net margin of 169.75%. The firm had revenue of $34.06 million for the quarter, compared to analyst estimates of $12.22 million.

Bicycle Therapeutics Stock Down 4.2%

Shares of NASDAQ:BCYC opened at $3.66 on Friday. The firm has a market cap of $256.16 million, a PE ratio of -1.80 and a beta of 1.68. Bicycle Therapeutics has a 12-month low of $3.33 and a 12-month high of $8.48. The company’s 50 day moving average price is $3.83 and its two-hundred day moving average price is $4.58.

Analyst Ratings Changes

BCYC has been the topic of several recent research reports. Zacks Research downgraded Bicycle Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Wednesday, October 14th. Weiss Ratings reissued a “sell (e+)” rating on shares of Bicycle Therapeutics in a research note on Friday, October 2nd. Jefferies Financial Group reaffirmed a “buy” rating and set a $10.00 price target on shares of Bicycle Therapeutics in a research note on Thursday. Needham & Company LLC lowered their price objective on shares of Bicycle Therapeutics from $15.00 to $14.00 and set a “buy” rating on the stock in a research note on Thursday, July 30th. Finally, Wall Street Zen upgraded shares of Bicycle Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday. Five research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $13.57.

Bicycle Therapeutics Company Profile

Bicycle Therapeutics plc is a biopharmaceutical company that develops medicines using its proprietary Bicycle molecule technology. Bicycle molecules are small, constrained peptides designed to bind selectively to biological targets while offering characteristics that may support tissue penetration, rapid clearance, and chemical synthesis. The company is primarily focused on creating therapies for cancer and other serious diseases.

Bicycle Therapeutics’ research programs include targeted therapeutics intended to deliver cytotoxic payloads to tumor cells, as well as immune-modulating treatments designed to activate or direct the immune system within the tumor microenvironment.